Philips Agreement, page-66

https://www.imbio.com/products/lung-density-analysis-inspiration/

I’m thinking Imbio’s LDAi might be the main product they push for lung cancer screening programs in Australia, US and other future programs elsewhere.

And perhaps also LTA too (seeking FDA approval in US soon) for (parts of) lung cancer screening programs too

https://www.imbio.com/products/lung-texture-analysis/

From Feb 2024 presentation:



Indeed we also offer a partner solution for lung nodules analysis - we partnered with, and are powering, Riverain’s program for those unaware:
https://www.imbio.com/news/imbio-and-riverain-technologies-partner-to-offer-a-comprehensive-ai-powered-lung-health-solution/

4DMedical‘s own XV products could arguably be used for this purpose too, and the combination of Imbio and 4DX products analysing a single CT means superior information for population wide lung cancer screening programs if we are fortunate to be selected for these.

Further, also from same presentation, I think the growth opportunity or even goal is to use just a single chest CT and run Imbio (and 4DMedical) analyses / products over these to help detect / triage for both lung disease and heart disease (e.g. CAC scoring, etc.)